Over the past few years, Google has expanded into life sciences, with venture capital investments, the creation of Calico and development of "smart" contact lenses giving it multiple beachheads in the industry. But the search giant's co-founders have reservations about getting deep into healthcare, saying regulations make it a "painful" sector in which to work.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
Pfizer and 23andMe have teamed up to identify genetic factors linked to inflammatory bowel disease. And with 23andMe trumpeting the fact that people can participate without leaving their homes, the study represents a continuation of Pfizer's interest in virtual trials.
In the years since the Affordable Care Act birthed the Patient-Centered Outcomes Research Institute, the group has committed resources to lowering barriers between those who participate in and run clinical trials. The latest element of this initiative has now come to fruition, with PCORI naming PatientPowered.us as the winner of its Matchmaking App Challenge.
The FDA has set aside $16 million for tracking which drugs are used, in what combinations and for how long, Regulatory Focus reports.
The National Institutes of Health (NIH) has awarded a clutch of big-name academic centers funding to create a database for studying motor neuron disorders. By embarking on a large-scale data generation drive and analyzing the resulting information, the collaborators hope to build profiles for Lou Gehrig's disease and other neuromuscular conditions.
Medidata has promised to review its financial controls after fraudsters made away with $4.8 million. Midlevel employees in the eClinical company's finance department reportedly made the transfer to an overseas bank account after receiving a request for $4.8 million.
The FDA's Mini-Sentinel has long since outgrown its "mini" moniker and is now ready to graduate from being a pilot project to being an integral part of the agency's drug-safety infrastructure. Many people welcome the program's progress, but doubts and dissenting voices remain.
From Our Sister Sites
Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while adding up to $400 million each--$1.6 billion in total--in fresh milestones.
Chicago-based Baxter International has inked a 200,000-square-foot lease in the heart of Cambridge, MA's biotech hub which will become the new research center of its soon-to-be-spun-out biopharma division, Baxalta.